We report a patient who underwent repeat orthotopic liver transplantation complicated by intraoperative blood loss of more than 59 litre. During liver transplantation, a constant rate propofol infusion was given and plasma samples were obtained throughout the procedure for propofol assay. Before the anhepatic phase of the procedure, plasma propofol concentrations reached a plateau at 1 µg ml -1 , and these concentrations were consistent with those predicted using a pharmacokinetic model. During the anhepatic phase of surgery, serum propofol concentrations increased progressively and exceeded those predicted by the pharmacokinetic model. Large intravascular fluid shifts associated with blood loss and subsequent blood replacement influenced plasma propofol concentrations observed in this patient.
Propofol (2,6 diisopropyl phenol) is a rapidly acting i.v. anaesthetic agent for induction and maintenance of general anaesthesia. Propofol is used during liver transplantation because its metabolism is not greatly affected by liver failure, but the pharmacokinetics of propofol during liver transplantation have not been defined fully. 1 During transplantation, propofol pharmacokinetics may be influenced by factors such as absence of hepatic metabolism during the anhepatic phase of liver transplantation and the large fluid volume shifts that often occur. We report a case of liver transplantation that was complicated by significant blood loss. This case demonstrates the influence of massive blood loss on plasma concentrations of propofol.
Case report
A 31-yr-old man who had a long history of liver disease as a result of hepatitis B infection presented for repeat orthotopic liver transplantation. Six years before, he had undergone liver transplantation but developed complications which included chronic ductopenic rejection, recurrent hepatitis B viral infection, cytomegalovirus hepatitis, portal hypertension with oesophageal varices and hepatorenal syndrome with impaired kidney function. One month before admission to our hospital the patient had increasing jaundice, nausea, vomiting, lethargy and ankle oedema. He was receiving prednisone, azathioprine, cyclosporin, lamivudine, © British Journal of Anaesthesia spironolactone, lactulose, cisapride, ranitidine, codeine phosphate and vitamin supplementation.
On examination he was cachectic and deeply jaundiced with stigmata of chronic liver dysfunction. He was alert, orientated and cooperative. He weighed 65 kg. He had an enlarged liver and spleen, moderate ascites and ankle oedema. Jugular venous pressure was mildly increased (2 cm H 2 O), but further examination of his cardiovascular system was unremarkable. On auscultation his chest was clear.
Relevant blood results are shown in Table 1 . An echocardiogram reported trivial mitral regurgitation with normal right and left ventricular function. A diagnosis of end-stage hepatic failure was made and urgent liver transplantation recommended.
Institutional Ethics Committee approval and informed consent were obtained. The patient received no premedication. A single i.v. cannula and radial arterial line were inserted under local anaesthesia. Morphine 20 mg was administered i.v. before induction. Anaesthesia was induced with propofol 150 mg, and initial neuromuscular block was achieved with succinylcholine 100 mg. The trachea was intubated and anaesthesia was maintained with infusion of propofol at a rate of 3 mg kg -1 h -1 combined with 0.5% isoflurane in 100% oxygen. The propofol infusion rate and isoflurane concentration were kept constant throughout operation. Ventilation was adjusted to maintain end-tidal carbon dioxide partial pressure at 4.7-6.0 kPa. Pancuronium 8 mg was given to maintain neuromuscular block, as guided by peripheral muscle twitch response to nerve stimulation. A large-bore i.v. cannula was inserted and a pulmonary artery catheter was passed into the pulmonary artery.
Transfusion of equal volumes of washed bank blood and fresh frozen plasma (FFP) was used to maintain right atrial pressure at 12-18 mm Hg. The blood-FFP mixture was stored in a graduated reservoir and delivered to the patient via a blood warming system in aliquots of 200 ml or greater using a 'Cobe' roller pump. This enabled accurate recording of the volume of blood administered to the patient. A cell saver was used to wash the bank blood, but because the patient was hepatitis B positive, his own blood was not salvaged during operation. Although blood loss was measured, this was considered to be a poor measure of total blood loss because of the large amount of blood lost onto the floor, drapes and swabs. We report the volume of blood transfused, averaged over time, to reflect blood loss. A further 3 litre of crystalloid was given during the procedure for delivery of other drugs.
During the surgical procedure, 5-ml blood samples were obtained for measurement of plasma concentrations of propofol at 5, 10, 15, 20 and 30 min and thereafter every 30 min until completion of surgery. At the beginning of the anhepatic phase of transplantation, specimens were obtained every 5 min for 30 min and then every 10 min for 90 min and thereafter every 30 min. After collection, samples were centrifuged and stored at -20°C. Plasma concentrations were measured using a reversed-phase, high-performance liquid chromatographic method with fluorescence detection. This involved addition of 4-tert-octylphenol as internal standard to plasma samples (0.1 ml), protein precipitation with acetonitrile 0.25 ml, centrifugation and direct injection of the supernatant into a C18 reversed-phase column using a methanol-water mobile phase. The coefficients of variation of the assay were 4.3% and 5.1% for propofol 10 and 1 µg ml -1 and the minimum quantifiable concentration was 50 ng ml -1 of plasma using a 0.1-ml sample. 2
Fig 1
Relationship between plasma concentrations of propofol (symbols), estimated plasma propofol concentrations based on pharmacokinetic modelling (broken line) and the pattern of blood transfused (shaded area).
As liver transplantation was complicated by the presence of adhesions and difficult surgical access, significant blood loss ensued. In total, the patient received 99 u. of homologous packed red blood cells, 130 u. of fresh frozen plasma, 30 u. of platelets and 3 litre of crystalloid. Over the 10 h of surgery the patient received 59.4 litre of the blood-FFP mixture. Intraoperative blood loss was associated with episodes of haemodynamic instability but systolic arterial pressure was maintained greater than 80 mm Hg throughout most of the procedure. Decreases in arterial pressure to less than 60 mm Hg occurred transiently at times of increased blood loss. Unfortunately, the surgeons were unable to successfully graft the donor liver and surgical haemostasis was difficult. Despite all attempts, control of bleeding was not possible and the patient died in the operating theatre. Assayed plasma propofol concentrations and estimated plasma propofol concentrations predicted by the pharmacokinetic model proposed by Tackley and colleagues 3 and the pattern of blood transfused are shown in Figure 1 . Liver transplantation can be described in terms of three phases: dissection, anhepatic (and reperfusion) and closing phases. During the dissection phase, before the anhepatic phase of liver transplantation, assayed propofol concentrations were similar to calculated concentrations, as predicted using the pharmacokinetic model for propofol. Despite the large volumes of blood transfused, plasma concentrations of propofol remained constant during this phase of surgery. After removal of the liver, at the beginning of the anhepatic phase of liver transplantation (4 h after the start of the procedure), plasma propofol concentrations increased gradually. During this period, rapid transfusion of blood products was followed by decreases in plasma propofol concentrations at 5.5 and 7 h. The liver was not grafted successfully and the patient remained anhepatic from the time the liver was removed until his death.
Discussion
We have reported the effects of severe hepatic impairment and massive blood loss on plasma propofol concentrations. The pharmacokinetics of propofol in healthy patients have been investigated extensively [4] [5] [6] and can be described in terms of a three-compartment model with a rapid distribution phase (T 1/2 α 3 min), rapid elimination (T 1/2 β 45 min) and a slower final phase of elimination (T 1/2 γ 300 min). Volume of distribution is large (11.3-13.3 litre kg -1 ) 7 and clearance is rapid. 8 Propofol is cleared predominantly by the liver but extrahepatic sites of metabolism in the lungs, kidney and intestines have been postulated. 9 The pharmacokinetics of propofol in patients with liver disease have also been investigated. During continuous infusion of propofol, plasma propofol concentrations may be slightly greater in patients with cirrhosis compared with controls. The volume of distribution is increased in cirrhosis but elimination half-life appears to be unchanged. 10 11 Plasma propofol concentrations during the anhepatic phase of liver transplantation were increased compared with a control group. 9 The influence of massive blood transfusion on the plasma concentrations of propofol has not been reported previously. Experimental haemorrhagic shock in animals appears to impair hepatic oxidative metabolism resulting in increased plasma concentrations of drugs but the influence of haemorrhagic shock on hepatic glucuronidation is unresolved. 12 In our patient, during the dissection phase of liver transplantation, plasma propofol concentrations were close to predicted concentrations, supporting the observation that propofol elimination is essentially unchanged in patients with severe liver disease. Significant blood loss with transfusion of propofol-free blood products during the dissection phase of transplantation did not influence measured plasma propofol concentrations. This may be explained by movement of propofol from the peripheral compartments back into the central compartments. Haemorrhagic shock may impair hepatic function. 12 13 However, during the dissection phase, plasma propofol concentrations did not increase significantly, indicating that the potential effects of impaired propofol metabolism caused by haemorrhage were minimal. At the beginning of the anhepatic phase of liver transplantation, plasma propofol concentrations increased, indicating that the liver is the predominant organ of metabolism for propofol.
Blood transfusion appeared to influence plasma propofol concentrations with rapid blood loss accompanied by rapid transfusion of blood products resulting in decreases in plasma propofol concentrations at 5.5 and 7 h after commencement of the procedure. The decrease in plasma propofol concentration was a result of dilution with propofol-free blood products. The rate of blood loss and replacement at these times was so great that plasma propofol concentrations decreased despite movement of propofol from the peripheral to the central compartments. While rapid transfusion of blood products at 5.5 h was followed by decreases in plasma propofol concentrations, concentrations started to decline at 5 h, approximately 20 min before the period of rapid blood transfusion. There are several possible explanations for this. During times of extreme blood loss there was sometimes a delay in delivering the required amount of blood to the patient. This delay was usually a result of the time taken to wash red blood 348 cells. This period of time represented extreme blood loss, with transfusion rates of up to 27 litre h -1 . We suggest that it is likely that the decrease in plasma propofol concentration at 5 h was caused by blood loss before rapid transfusion and subsequent movement of interstitial fluid into the intravascular space, diluting the plasma propofol concentration. It is also possible that the propofol infusion was reduced at this time as a result of a propofol syringe change or obstructed delivery line, although there was no recorded evidence of this during the anaesthetic. It is interesting to note that despite rapid blood loss accompanied by rapid transfusion of blood products, plasma propofol concentrations were at all times above those predicted.
In summary, we have confirmed that plasma propofol concentrations were affected minimally by severe hepatic dysfunction. During the anhepatic phase of liver transplantation, plasma propofol concentrations increased because of cessation of hepatic metabolism. Massive haemorrhage accompanied by volume replacement decreased plasma propofol concentrations.
